Sitemap
- February 2007 Monthly Safety Labeling
- FDA Approves New Treatment For Crohn's Disease
- November 2006 Monthly Safety Labeling
- August 2006 Safety Labeling Changes
- Enhanze Technology Clinical Trial Demonstrated Improved Absorption
- Halozyme Therapeutics Reports Positive Results For Enhanze Technology ...
- First BanCorp FY06 Profit Declines On Higher Expenses - Update [FBP]
- Unica Reveals Preliminary Q3 Results - Quick Facts [UNCA]
- Three Studies Suggest Abbott's HUMIRA (adalimumab) May Improve Work ...
- Elan Elevates Its Game
- A recruiter's dream team
- Investigational Study Demonstrated a Re-Establishment of Clinical ...
- Scientist tycoon
- Abbott’s HUMIRA® (Adalimumab) Approved in the European Union for ...
- Business briefs
- Abbott's Humira wins European approval as treatment of Crohn's disease
- European Commission OKs Abbott's Drug
- Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union
- Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the ...
- Abbott Ups Humira Sales Target To More Than $2.8 Billion for 2007
- Big Pharma blurring the lines with Big Biotech
- IDM Pharma Names Timothy P. Walbert as President and CEO
- IDM Pharma Names Timothy P. Walbert as President and CEO
- Lake Co. briefs: Abbott data positive for Crohn's disease
- Rheumatoid Arthritis - New Therapies and Higher Costs
- GAITHERSBURG, Maryland
- Strolling for a Cure: Arthritis walk to benefit foundation, research
- Abbott Laboratories' Humira Will Replace Centocor's Remicade as the ...
- Priced out of pain relief
- Briefs: Akorn posts loss, revenue falls by half
- Biotech Stocks: Drug stocks end higher; biotech stocks slip
- Out of the Gate: Abbott Labs Gains
- Abbott Seeks Additional Humira Approval
- Abbott seeks US, EU approvals for Humira to treat juvenile rheumatoid ...
- Abbott seeks Health Canada approval of HUMIRA(R) for psoriasis
- Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R ...
- New Therapy For Patients With Crohn's Disease Identified By ...
- Abbott Reviews 2006 Accomplishments At Annual Shareholders’ Meeting
- Abbott Labs 1Q Profit Falls 19 Percent
- Abbott CEO fights back in dispute over HIV drug
- Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting
- Merck, Schering, Buoyed by Medicare, May Lead Stocks (Update1)
- Abbott Closer to New Humira Approval
- Abbott's Humira recommended for approval by Euro Medicines Agency for ...
- Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from ...
- Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from
- More than skin deep: Psoriasis can also affect joints
- Royalty Pharma and InNexus Biotechnology Announce Agreement Regarding ...
- It pays to advertise
- Committee for Medicinal Products for Human Use Post-authorisation ...
- EU panel recommends Abbott Crohn's drug
- Increasing Number of Arthritis Cases Drive the Economic Impact of ...
- Abbott Reports 15.5 Percent Sales Growth in First Quarter
- J&J, NYU charge Abbott with infringement
- UW-La Crosse student teacher Abby Ryan conducts her third grade class ...
- Earnings Preview: Abbott Laboratories
- Drug-plant outsourcing is sad news
- Big Pharma to roll out earnings next week
- Pearl Jam's McCready Keeps Rocking For Crohn's
- Humira is effective in psoriasis
- FDA has approved Humira for Crohn's disease
- MIDWEST BRIEFS
- Positive Report Boosts U.S. Steel. AT&T Aims To Buy Italian Stake...
- Abbott Seeks U.S. And E.U. Regulatory Approval For HUMIRA ...
- Abbott files Humira for psoriasis
- Latest News
- Inflammatory bowel disease - Crohn's disease
- Week of: February 25
- RA and Self Esteem
- Taking pharma to the big screen
- FDA approves new Crohn's disease treatment
- FDA approves new Crohn's disease treatment
- Today's Globe: vitamins, HPV, bird-flu, polio, Crohn's disease
- Abbott gets FDA approval to sell arthritis drug for Crohn's disease
- 2nd UPDATE: UCB FY06 Net Profit +36% On Capital Gains,Keppra
- HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment Of Crohn's ...
- Abbott’s Humira will treat Crohn’s
- Humira approved for Crohn's
- Abbott gets FDA approval to sell arthritis drug for Crohn's disease
- US clears use of Abbott drug for Crohn's disease
- US clears use of Abbott drug for Crohn's disease
- Humira Approved for Crohn's Disease
- Sector Wrap: Pharmaceuticals fall
- Humira Approved for Crohn's Disease
- FDA Approves New Treatment For Crohn's Disease
- Abbott gets OK to promote Humira for Crohn's
- FDA approves Humira (adalimumab) for Crohn's disease
- Humira Approved for Crohn's Disease
- Top Classes of Biologics with 2006 Sales of US$ 63.8 Billion
- Genentech loses patent dispute with MedImmune
- Johnson & Johnson hits the big screen with ad
- New Drug Helps Ease Psoriasis
- New Drug Helps Ease Psoriasis
- Centers for Medicare and Medicaid Services (CMS) Declines Cyberonics ...
- Psoriasis Patients Show Significant Improvement In Symptoms With ...
- Governor aims to insure all
- Business briefs
- Zacks Analyst Blog Highlights: Motorola, Apple, Abbott Labs, Boston ...
- Abbott shares up on earnings
- Abbott Laboratories swings to 4Q loss related to Kos acquisition
- 2nd UPDATE: Abbott Posts 4Q Net Loss On Kos Takeover
- Abbott posts loss on Kos purchase
- Abbott Gets Past Estimates
- UPDATE 4-Abbott posts loss on Kos purchase
- More Humira MSN Newsfeeds...
- DIREVO announces validation of bestMab(TM)
- News and Press release service TransWorldNews
- News: American College of Rheumatology presents recommendations for rheumatoid arthritis therapy. Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business
- Abbott's Humira tames Crohn's in 29 pct of patients | Industries | Healthcare | Reuters
- News - Addition of Methotrexate to Infliximab Offers No Improvement for Crohn's Disease: Presented at DDW
- News - About 39% of Crohn's Disease Patients Achieve Remission With Certolizumab After Infliximab Failure: Presented at DDW
- News - Crohn's Disease Patients Sustain Remission and Improvement for at Least 2 Years With Adalimumab Therapy: Presented at DDW
- News - Natalizumab Reduces Hospitalisations in Patients With Crohn's Disease: Presented at DDW
- Abbott's HUMIRA (adalimumab) Recommended By NICE For The Treatment Of Severe Active Ankylosing Spondylitis
- Grand Forks Herald
- Abbott's Humira Found Effective in Crohn's Disease Extension Study - Health - redOrbit
- Abbott Labs growth helped by medical technology
- Abbott's Humira tames Crohn's in 29 pct of patients | Industries | Healthcare | Reuters
- FDA Probes Possible Link In Arthritis Drugs, Cancer In Kids
- FDA to study if link exists between childhood cancer and Abbott's Humira -- Social Issues, Abbott Laboratories -- chicagotribune.com
- New Drug for Rheumatoid Arthritis Looks Promising.
- Rheumatoid arthritis hope as NICE set to reconsider guidance - Healthcare Republic News
- Nursing in Practice - Joy as arthritis drugs reviewed
- Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
- RTTNews - Quick facts Articles, Positive EPS Surprises, News Analysis, Earnings, Audio News....
- Briefing.com Business News: Market Report -- In Play (HALO) - MSN Money
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- Daytrading, Eminis, Forex trading, Swing Trading STOCK ALERT - 568793
- Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
- Abbott :: Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease - PipelineReview.com | Business Intelligence Center
- Treatment of Crohn Disease with Anti-Tumor Necrosis Factor Agent -- 146 (12): I-20 -- Annals of Internal Medicine
- GAIN for Loss: Adalimumab for Infliximab-Refractory Crohn Disease -- Mannon 146 (12): 888 -- Annals of Internal Medicine
- Abbott Launches Humira (Adalimumab) For Crohn's Disease
- PharmaTimes - Login
- RTTNews - Quick facts Articles, Positive EPS Surprises, News Analysis, Earnings, Audio News....
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 562879
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 562908
- Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
- Abbott :: Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
- New Data Shows That Early Treatment Of Rheumatoid Arthritis With Abbott's HUMIRA (adalimumab) Can Keep Patients In Work
- New class of biologic may bring psoriasis relief
- PR Newswire : New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
- Abbott :: New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
- Briefing.com Business News: Market Report -- In Play (ABT) - MSN Money
- Abbott's HUMIRA® (Adalimumab) Approved In The European Union For The Treatment Of Crohn's Disease
- PharmaTimes WorldNews| Daily pharmaceutical news | Abbott's Humira approved in the EU for Crohn's disease
- Abbott's Humira wins European approval as treatment of Crohn's disease - Forbes.com
- European Commission OKs Abbott's Drug - Forbes.com
- European Commission OKs Abbott's drug | Latest News | News | Hemscott
- PharmaLive: Abbott's Humira (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Abbott :: Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Disease > HUMIRA Approved In EU For Treatment Of Crohn's Disease
- EU Approves Abbott's Humira for Crohn's Disease
- Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease - PipelineReview.com | Business Intelligence Center
- Abbott's Humira(r) (Adalimumab) Gets Approval by EU for Crohn's Disease Treatment
- New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
- New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
- WebWire | New Analysis of Data Shows Treatment with Abbotts HUMIRA (adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
- Therapeutics Daily
- Abbott sees positive Humira data | Latest News | News | Hemscott
- Abbott Sees Positive Humira Data - Forbes.com
- United Press International - Health Business - Briefing
- Data shows Humira effective against Crohn's :: CHICAGO SUN-TIMES :: Business
- New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
- PharmaTimes - Login
- Disease > Treatment With Humira Reduced Hospitalization For Patients With Crohn's Disease
- New Analysis Of Data Shows Treatment With Abbott's HUMIRA® Significantly Reduced Disease-Related Hospitalization For Patients With Crohn's
- Biotech drugs contribute heavily to Big Pharma sales - May. 29, 2007
- Latest News | News | Hemscott
- Abbott seeks US, EU approvals for Humira to treat juvenile rheumatoid arthritis - Forbes.com
- Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid Arthritis
- CNW Telbec
- PharmaTimes - Login
- Abbott: another promising year for Humira - Pharmaceutical Business Review
- Treatment of Crohn Disease with Anti-Tumor Necrosis Factor Agent -- , -- Annals of Internal Medicine
- News - Researchers Identify New Therapy for Patients with Crohn's Disease
- PharmaLive: Abbott's Humira (Adalimumab) Receives Positive Opinion from EMEA for the Treatment of Crohn's Disease
- Adalimumab is an effective treatment for refractory Crohn's disease
- Adalimumab shows potential for Crohn's disease
- Log In Problems
- egoli - News & Views
- Peptech ASX: PTD - Peptech & EvoGenix Merge to Form Antibody Powerhouse - Dr John Chiplin and Dr Merilyn Sleigh
- Peptech and EvoGenix Merge to Form Antibody Powerhouse
- News: Peptech and EvoGenix Merge for about $128.55M. Genetic Engineering News - Biotechnology from Bench to Business
- PharmaTimes WorldNews| Daily pharmaceutical news | Australian biotechs Peptech and EvoGenix set to merge
- Deal takes pep out of PepTech shares - Business - Business - theage.com.au
- Peptech and EvoGenix Merge to Form Antibody Powerhouse
- Peptech and EvoGenix Merge to Form Antibody Powerhouse
- Australia's Peptech, EvoGenix to merge in cash and shares deal
- PharmaLive: Peptech and Evogenix Merge to Form Antibody Powerhouse
- AdelaideNow... Peptech all set for $433m merger
- Peptech and Evogenix Merge to Form Antibody Powerhouse - PipelineReview.com | Business Intelligence Center
- Peptech, Evogenix to merge - Breaking News - Business - Breaking News
- Peptech, EvoGenix merger to create giant - Breaking News - Business - Breaking News
- Peptech, EvoGenix merger to create giant - Breaking News - Business - Breaking News
- Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn.s Disease
- AGCO "equal weight," target price raised - update | newratings.com
- Corrections Corp of America "overweight," target price raised - update | newratings.com
- DealerTrack Holdings "overweight," target price raised – update | newratings.com
- Checkpoint Systems "equal weight," target price raised - update | newratings.com
- Techwell "overweight," target price reduced - update | newratings.com
- Liz Claiborne "equal weight," target price reduced - update | newratings.com
- Strayer Education "equal weight," target price raised - update | newratings.com
- More Humira News Articles...
- Famvir, Humira.(NEW & APPROVED)(drug licensing)(drug overview): An article from: Family Practice News
- Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-Cell-targeted therapies ... from: Journal of Drugs in Dermatology
- Mixing immunomodulators and pregnancy.(Guest Editorial): An article from: Skin & Allergy News
- Adalimumab + methotrexate slows RA progression; about 60% achieve ACR 20. (rheumatoid arthritis).(Clinical Rounds): An article from: Internal Medicine News
- Adalimumab trumps methotrexate for psoriasis.(Dermatologic Therapy): An article from: Skin & Allergy News
- Adalimumab results best yet in juvenile arthritis.(Clinical Rounds): An article from: Pediatric News
- Methotrexate trumped by adalimumab for psoriasis.(Skin Disorders): An article from: Family Practice News
- Adalimumab response best yet in juvenile rheumatoid arthritis.(Clinical Rounds): An article from: Skin & Allergy News
- YAZ, Olux, Humira, Cymbalta.(New & Approved): An article from: Skin & Allergy News
- TNF-alpha Inhibitors (Milestones in Drug Therapy)
- Serious-infection rates similar among biologics: in a British registry, incidence rates for three agents were 52.6, 52.1, and 62.4 per 1,000 patient-years.(Rheumatology): ... An article from: Internal Medicine News
- Etanercept, adalimumab look safe in pregnancy.(Dermatologic Therapy)(Medical condition overview): An article from: Skin & Allergy News
- Cymbalta for GAD, Humira for Crohn's.(New & Approved): An article from: Family Practice News
- Humira.(NEW & APPROVED): An article from: Internal Medicine News
- Angeliq, Humira.(New & Approved): An article from: Family Practice News
- Datu Si Gunja
- FDA recognizes adalimumab's joint protective effects in psoriatic arthritis.(News): An article from: Skin & Allergy News
- Adalimumab clears phase III psoriasis hurdle.(Dermatologic Therapy): An article from: Skin & Allergy News
- Adalimumab offered at no cost to seniors who lack drug coverage. (Until Medicare Drug Benefit Enacted).: An article from: Internal Medicine News
- Adalimumab holds Crohn's disease in check: a larger study is underway to definitively assess the drug's long-term efficacy for preventing recurrence.(Gastroenterology)(Drug ... : An article from: Internal Medicine News
- Adalimumab maintains Crohn's disease remission; the subcutaneously injected drug is currently approved by the FDA for the treatment of arthritis.(Digestive ... An article from: Family Practice News
- Third TNF-blocker targets psoriatic arthritis.(Rheumatology)(tumor necrosis factor inhibitor): An article from: Internal Medicine News
- Adalimumab can suppress Crohn's after infliximab fails.(Gastroenterology): An article from: Internal Medicine News
- Adalimumab advised for recalcitrant psoriasis.(Dermatologic Therapy): An article from: Skin & Allergy News
- Twice-monthly Adalimumab eases RA symptoms. (New Humanized Monoclonal Antibody).(Brief Article): An article from: Family Practice News
- New treatments for IBD show promise in trials.(Rx)(Inflammatory bowel diseases): An article from: Internal Medicine News
- Invasive cryptococcosis and adalimumab treatment.(LETTERS)(Letter to the editor): An article from: Emerging Infectious Diseases
- Psoriasis, psoriatic arthritis improved with adalimumab.: An article from: Internal Medicine News
- Pocket Pharma: Adalimumab (Pocket Pharma)
- Adalimumab offered free for certain seniors. (Costly Rheumatoid Arthritis Drug).(antirheumatic agent): An article from: Family Practice News
- Adalimumab looks good for psoriasis.(Skin Disorders): An article from: Family Practice News






